Navigation Links
European research initiative EUREKA presented at Research & Technology for the first time
Date:2/10/2010

For the first time the European research initiative EUREKA will be represented with its own stand at Research & Technology, which forms part of HANNOVER MESSE 2010 (19-23 April). This presentation underlines the strategic importance of the Innovations Market for Research and Development in Hall 2.

"We want to emphasize the contribution that EUREKA makes as a central European platform with respect to the international networking of industrial research, technological progress and innovation. HANNOVER MESSE affords an ideal setting due to its huge high-tech diversity and international scope, not least the exhibitors and visitors from numerous countries. No other single event offers us such a convincing combination of important factors Hanover is uniquely suited as a showcase for our initiative", says Luuk Borg, Director of the EUREKA Secretariat.

EUREKA is an intergovernmental organisation. The governments of all its member nations and the European Commission will be represented in Hanover. The policy guidelines of the EUREKA initiative and the support of the various European projects within it are determined through the decentralised network of its members. The Chairmanship alternates between the individual member countries and is responsible for coordinating political and strategic development. The nation that holds the Chairmanship is represented in each of the constituent bodies that make up EUREKA's organisational structure.

Germany holds the chair of the EUREKA initiative until summer 2010 Germany will chair EUREKA from 1 July 2009 until June 2010. The role of the Chairmanship is to sustain the momentum of the work and pursue the strategic development of EUREKA by actively encouraging the network's efforts to develop a European research and innovation area. One key goal is to support and promote the participation of SMEs in international collaborative projects.

Located within the international mix of high-tech and business afforded by HANNOVER MESSE, the trade fair Research & Technology, in tandem with the EUREKA initiative, offers ideal conditions for technology and research-led companies to find business leads in the international arena. The event is a platform for knowledge transfer and matchmaking at the highest level.

A further highlight linked to EUREKA's appearance at HANNOVER MESSE will be the presence of the three EUREKA Innovation Award finalists. The finalists will complete the line-up of top-flight speakers from the different EUREKA Clusters addressing the visitors, who come from across the globe to what is undeniably the world's most important technology event.


'/>"/>

Contact: Piotr Pogorzelski
piotr.pogorzelski@es.eureka.be
322-777-0979
EUREKA
Source:Eurekalert

Related biology technology :

1. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
2. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
3. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
4. Kline Study: Better Brushing Habits Boost European Oral Care Sales
5. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
6. European Centre for Modern Drug Discovery Established in Hamburg
7. SAFC Expands European Commercial Manufacturing and Storage Capacities With $10 Million Investment
8. Cardica Receives European CE Mark for C-Port Flex A System for Use in Coronary Artery Bypass Surgery
9. Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting
10. Intellect Neurosciences, Inc. Obtains Validation of European Patent for Alzheimers Vaccine in 19 Countries
11. Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Hodgkins Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is ... has received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval ... Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods ...
(Date:6/23/2016)... FRANCISCO , June 23, 2016   EpiBiome ... has secured $1 million in debt financing from Silicon ... ramp up automation and to advance its drug development ... its new facility. "SVB has been an ... beyond the services a traditional bank would provide," said ...
(Date:6/23/2016)... NC (PRWEB) , ... June 23, 2016 , ... In ... University Hospital in Denmark detail how a patient who developed lymphedema after being treated ... tissue. The results could change the paradigm for dealing with this debilitating, frequent side ...
Breaking Biology Technology:
(Date:6/1/2016)... 1, 2016 Favorable Government Initiatives ... and Criminal Identification to Boost Global Biometrics System Market ... TechSci Research report, " Global Biometrics Market By ... and Opportunities, 2011 - 2021", the global biometrics market ... on account of growing security concerns across various end ...
(Date:5/12/2016)... 2016 WearablesResearch.com , a brand of ... results from the Q1 wave of its quarterly wearables ... consumers, receptivity to a program where they would receive ... insurance company. "We were surprised to see ... Michael LaColla , CEO of Troubadour Research, "primarily because ...
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
Breaking Biology News(10 mins):